>Cancer diagnostics company Biomoda has been accepted as an associate member of the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute focused on the development of molecular technologies for the screening, early diagnosis, and target-based treatment of cancer.
"The EDRN is at the forefront of biomarker research," Biomoda President John Cousins said. "Our membership opens the door to extraordinary opportunities for collaborative research with our scientific peers who are working in the areas of minimally invasive diagnostics and targeted therapies for cancer."
In addition to Biomoda's first product, designed for early detection of lung cancer, the company is developing diagnostic assays for oral, cervical, breast, colorectal, and bladder cancers.
